The global neurological biomarkers market size reached US$ 6.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 14.6 Billion by 2027, exhibiting a growth rate (CAGR) of 13.5% during 2022-2027.
Neurological biomarkers refer to biological indicators present in the blood or cerebral spinal fluid (CSF). They help identify the pathogenicity and heterogeneity of neurological disorders, develop personalized treatment, and calculate the pharmacological responses of a specific therapy. Consequently, neurological biomarkers are extensively used in early diagnosis and progress monitoring of brain disorders, including epilepsy, tumor, Alzheimer's, and Parkinson's disease. At present, they are available in imaging, metabolomics, proteomics, and genomics product types.
Market Opportunities and Trends:
- The increasing prevalence of various neurological disorders and the rising need for non-invasive diagnostics are primarily driving the market growth. Neurological biomarkers detect disorders at the preclinical stage, permit the identification of potential targets for intervention, and identify novel targets for therapeutic intervention.
- Moreover, the growing uptake of biomarkers in the healthcare sector to provide early diagnosis, differentiate specific diseases and their sub-types, and develop personalized treatments is supporting the market growth. In line with this, rapid advancements in mass spectrometry and imaging procedures are acting as other growth-inducing factors. Furthermore, the advent of digital biomarkers by pharmaceutical companies to drive the value of drug assets, reshape the understanding of health and disease, overcome the common challenges of on-patient recruitment and retention, and conclude clinical trial decisions are expanding the market growth.
- Besides this, the escalating requirement for faster drug development solutions, the fueling number of clinical trials, and ongoing research and development (R&D) activities to enhance product efficacy are creating lucrative opportunities for market growth.
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
Request to Get the Sample Report: https://www.imarcgroup.com/neurological-biomarkers-market/requestsample
Competitive Analysis and Segmentation:
The competitive landscape of the global neurological biomarkers market has been studied in the report with the detailed profiles of the key players operating in the market.
Market Key Players List:
- Abbott Laboratories (NYSE: ABT)
- Acumen Pharmaceuticals Inc. (NASDAQ: ABOS)
- Athena Diagnostics (Quest Diagnostics)
- Banyan Biomarkers Inc.
- Bio-Rad Laboratories Inc.
- Immunarray Pvt. Ltd.
- Myriad Rbm Inc. (Myriad Genetics Inc.)
- Proteome Sciences Plc
- Thermo Fisher Scientific Inc.
Market Segmentation:
The report has segmented the neurological biomarkers market on the basis of type, application, end use and region.
Breakup by Type:
- Genomic Biomarkers
- Proteomic Biomarkers
- Metabolomic Biomarkers
- Imaging Biomarkers
- Others
Breakup by Application:
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
Breakup by End Use:
- Hospital Laboratories
- Clinical Diagnostic Centers
- Research Organizations
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=3181&flag=C
Key Highlights of the Report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Browse More Related Reports:
Brain Computer Interface Market
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCโs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companyโs expertise.
Contact Us:
IMARC Group
134 N 4th St
Brooklyn, NY 11249, USA
Email: [email protected]
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800
Read Newsletter: https://www.linkedin.com/newsletters/industry-news-about-6929400456628637696
